Avalon GloboCare Corp. (AVCO) Stock Analysis

What Avalon GloboCare Corp. does

Avalon GloboCare Corp., along with its affiliated entities, possesses and manages commercial real estate assets across both the United States and the People's Republic of China. Beyond its real estate ventures, the company provides a suite of medical consulting offerings. These encompass conducting research studies, delivering executive education, issuing daily online executive briefings, and furnishing customized expert advisory services. Furthermore, it offers specialized consulting and management expertise in fields such as immunotherapy and services for obtaining second opinions or referrals. A core part of its biopharmaceutical pipeline includes two prominent CAR-T cell therapy candidates. AVA-001, an anti-CD19 therapy, has successfully concluded its initial human clinical trial for treating relapsed/refractory B-cell lymphoblastic leukemia. Meanwhile, AVA-011 has finished its preclinical laboratory evaluations and is currently advancing through the IND-enabling process development phase, which aims to produce cGMP-grade AVA-011 CAR-T cells. The company is also engineering an RNA-based FASH-CARTM cell therapy platform. Furthermore, Avalon GloboCare is involved in creating avalon clinical-grade tissue-specific exosomes (ACTEX). It collaborates with the Massachusetts Institute of Technology (MIT) to identify therapeutic and diagnostic targets using QTY-code protein design technology. This collaboration specifically extends to employing the QTY code for the invention of a hemofiltration device designed to manage Cytokine Storm. In partnership with Arbele Limited, it engages in the co-development of advanced, transposon-based, multi-target CAR-T, CAR-NK, and various other immune effector cell therapeutic approaches. The company has also forged a strategic alliance with the University of Natural Resources and Life Sciences in Vienna, Austria, focused on devising an S-layer vaccine for intranasal or oral administration, targeting SARS-CoV-2 and the coronavirus responsible for COVID-19. Additionally, it develops Avalon Cell and Avalon Rehab programs and actively champions standardization initiatives within the exosome industry. Its corporate headquarters are situated in Freehold, New Jersey.

Key metrics

ETFs linked to AVCO

Broad-market and Real Estate sector ETFs an investor holding Avalon GloboCare Corp. is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how AVCO fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Avalon GloboCare Corp.?

Avalon GloboCare Corp. trades under the ticker AVCO on NASDAQ.

Which exchange is AVCO listed on?

AVCO is listed on NASDAQ.

What sector does Avalon GloboCare Corp. operate in?

Avalon GloboCare Corp. is classified in the Real Estate sector (Real Estate - Services industry).

How can PortView help analyze AVCO in a portfolio?

PortView shows AVCO's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.